Imunon is a clinical-stage biotechnology company with no approved products or revenue, focused entirely on developing IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer. IMNN-001 is delivered intraperitoneally — directly into the abdominal cavity — and uses a non-viral DNA delivery system to instruct immune cells to produce IL-12, an immune-activating cytokine, at the tumor site. By localizing IL-12 delivery, Imunon avoids the severe systemic toxicity that has historically made IL-12 unworkable as a drug. IMNN-001 is designed to remodel the tumor microenvironment and is administered alongside standard chemotherapy. In its Phase 1/2 trial (OVATION 2, 113 patients), IMNN-001 plus standard of care produced a median 14.7-month overall survival benefit versus chemotherapy alone. Imunon is now running OVATION 3, a Phase 3 pivotal trial focused on an HRD-positive subgroup of newly diagnosed advanced ovarian cancer patients, with full enrollment targeted by late 2028. Imunon also has a secondary DNA-based vaccine platform, PlaCCine, for which it is seeking a partner or buyer after completing a small Phase 1 COVID-19 booster study. Imunon manufactures IMNN-001's active ingredient at its own facility in Huntsville, Alabama, and contracts out fill/finish. The company funds operations entirely through equity issuances and has acknowledged going-concern doubt, with a cash runway of roughly six months as of late 2025.